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Effect of L-carnitine on diabetic neuropathy and ventricular
dispersion in patients with diabetes mellitus
Hızır ULVİ, Recep AYGÜL, Recep DEMİR

Aim: Diabetes is a common cause of polyneuropathy. Cardiac arrhythmias and markedly increased mortality rate have
been demonstrated in patients with diabetic neuropathy and also demonstrated that abnormally prolonged QT dispersion
interval (QTd) is associated with a higher risk of ventricular arrhythmias and sudden death. We investigated the efficacy
and tolerability of L-carnitine (LC) in the treatment of diabetic neuropathy and ventricular dispersion, mainly by
evaluating the effects of treatment on electrophysiological parameters.
Materials and methods: We recruited 30 patients with type I or type II diabetes (mean age: 60 ± 9 years, range: 36-75;
18 males, 12 females) meeting clinical and neurophysiological criteria for diabetic neuropathy. All of the patients were
given LC 2 g/day for 10 months. Blood glucose regulation was maintained by diet, oral antidiabetic, or insulin. To
determine the nerve functions electrophysiologically, superficial electrode distal latency, amplitude, nerve conduction
velocity in median and ulnar nerves in the upper extremities and peroneal, tibial and sural nerves in the lower extremities
and F response in motor nerves were studied. Resting 12-lead electrocardiograms were recorded for measurements of
QTd, corrected QTd (QTcd), JT dispersion (JTd), and corrected JT dispersion (JTcd).
Results: After 10 months of treatment, median, ulnar, and tibial nerves’ motor nerve conduction velocities (P < 0.05) and
M-wave amplitudes (P < 0.05) increased; distal latencies and the F-wave latencies (P < 0.05) decreased; ulnar, sural, and
median sensory nerve action potential amplitude (P<0.01) and nerve conduction velocities (P < 0.05) increased; distal
latencies (P < 0.05) decreased; and , QTd, QTcd, JTd, and JTcd (P < 0.05) decreased significantly when compared to basal
values. The greatest changes in sensory nerve action potential amplitude and ventricular dispersion parameters were
observed in the sensory sural nerve and QTcd, respectively. LC was well tolerated over the study period.
Conclusion: LC, well tolerated by diabetic patients, may improve peripheral neuropathy and ventricular dispersion and
may be useful in preventing the increased incidence of arrhythmias and sudden death observed in such patients. Larger
clinical trials are needed to confirm these data before changes to clinical practice can be advocated.
Key words: L-carnitine, diabetic polyneuropathy, electromyography, ventricular dispersion

Diabetik polinöropatili hastalarda ventriküler dispersiyon üzerine
karnitinin etkinliği
Amaç: Diyabet en yaygın polinöropati sebebidir. Diabetik polinöropatili hastalarda kardiyak ritim ve ventriküler
dispersiyon bozukluklarının ani ölümlere sebep olduğu ve mortaliteyi artırdığı gösterilmiştir. Bu çalışmada, diabetik
polinöropatili hastalarda karnitinin ventriküler dispersiyon parametreleri ve nöropati üzerine etkinliğini ve yan etkilerini
araştırdık.
Yöntem ve gereç: Çalışmamıza polinöropatili 30 (18 erkek, 12 kadın) diabetik hasta alındı. Hastalara 10 ay boyunca 2
gr/gün karnitin uygulandı. Tedavi öncesi ve sonrası olguların hepsinde üst ekstremitelerde median ve ulnar, alt
ekstremitelerde peroneal, tibial ve sural sinirlerde distal latans, amplitüd, sinir ileti hızı, motor sinirlerde F yanıtı çalışıldı.
Ayrıca 50 mm/sn hızında 2 mV amplitüdünde standart 12 derivasyon elektrokardiyografi (EKG) çekimleri yapıldı.
Ortalama QT, JT, QTc, JTc, RR intervali, QT, JT, QTc, JTc dispersiyonu (d) saptandı.
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Bulgular: İncelenen tüm sinirlerde ileti parametrelerinin hepsinde iyileşme gözlendi. Bazal değerlerle karşılaştırıldığında
median, ulnar ve tibial sinirlerin motor ileti hızları (P < 0,05) ve bileşik kas aksiyon potansiyelleri (P < 0,05) anlamlı
olarak artmış; distal latans ve F-cevabı latansları (P < 0,05) düşmüştü; ulnar, sural ve median sensoriyal ileti hızı
amplitutleri (P<0,01) ve ileti hzları (P < 0,05) anlamlı olarak artmış; distal latansları (P < 0,05) düşmüştü. QTd, QTcd,
JTd, ve JTcd (P < 0,05) anlamlı olarak düşmüştü. En belirgin düzelme sural sinir sensorial aksiyon potansiyelinde ve
QTcd gözlendi. Karnitin çalışma periyodunca iyi tölere edildi.
Sonuç: Karnitin tedavisi ciddi bir yan etki olmaksızın ventriküler dispersiyon ve elektrofizyolojik değerlerde belirgin
düzelme sağlamıştır. Ancak, ilacın etkinliği ve güvenilirliği açısından daha uzun süreli ve geniş skalalı çalışmalara
gereksinim vardır.
Anahtar sözcükler: Diabetik nöropati, L-karnitin, elektromyografi, ventriküler dispersiyon

Introduction
A common complication of diabetes mellitus is
peripheral neuropathy that can affect both somatic (1)
and autonomic nervous systems (2), and the
pathophysiological characteristics of diabetic
neuropathy are complicated. A variety of hypotheses,
including biochemical and vascular factors
attributable to the reversible metabolic consequences
of hyperglycemia, insulin deficiency, or both for the
pathogenesis of this complication, have been proposed
(3-5). Hyperglycemia is proposed to promote
oxidative stress and generate reactive oxygen species
(ROS), leading to inhibit mitochondrial respiratory
enzymes and promote neuronal apoptosis (6,7).
Insulin deficiency can promote alterations in fatty
acid metabolism via blockade of the conversion of
linoleic acid to linolenic acid (8), perturbing the
production of vasodilating eicosanoids (9,10). Also,
the accumulation of long-chain fatty acid esters
disturbs cellular metabolism and membrane functions
(11).
Carnitine and its short-chain esters facilitate
transport of long-chain fatty acids across the inner
mitochondrial membrane for β-oxidation, thereby
promoting energy availability and preventing toxic
accumulation of long-chain fatty acids (12).
Furthermore, carnitine deficiency in diabetic tissues
has received considerable attention concerning its role
in the pathogenesis of diabetic neuropathy (13,14).
Nakamura et al. (15) also reported that there was a
close relationship between increased polyol pathway
activity and carnitine deficiency in the development
of diabetic neuropathy, and that an aldose reductase
inhibitor and LC have therapeutic potential for the
170

treatment of diabetic neuropathy. Carnitine uptake
into cells is partially dependent on Na+/K+-ATPase
(16). It is well known that decreased Na+/K+-ATPase
activity in nerves can be ameliorated by treatment
with aldose reductase inhibitors in diabetic rats (17).
A prolonged QT interval, as measured with a
standard electrocardiogram (ECG), is associated with
an increased risk of arrhythmias and sudden death
(18). In addition, QTd appears to be a better
prognostic marker than maximum QT interval,
particularly in patients without previous cardiac
diseases (19). Wheeler et al. (20) reported that
diabetic patients with autonomic neuropathy have
decreased the heart rate variability. Moreover, the
autonomic nervous system effects the QT interval and
QT prolongation observed in diabetic patients with
autonomic dysfunction (21). The effect of LC on the
increased QTd has never been studied. We
investigated the efficacy of LC in the treatment of
diabetic neuropathy and increased ventricular
dispersion.
Material and methods
We recruited 30 patients with type I or type II
diabetes (mean age: 60 ± 9 years, range: 36-75 years;
18 males, 12 females) meeting clinical and
neurophysiological criteria for diabetic neuropathy.
The demographic characteristics of patients are
presented in Table 1. All of the patients were given LC
2 g/day for 10 months. Blood glucose regulation was
maintained by diet, oral antidiabetic, or insulin. There
was no other systemic or neurological disorder that
can lead to peripheral neuropathy except diabetes
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mellitus in these cases and all of them were examined
10 months before and after the treatment. Changes in
the
neuropathy
symptom
and
deficit,
electrophysiological peripheral-nerve conduction
studies, and the ventricular dispersion parameters
were assessed at the end of 10 months. To determine
the nerve functions electrophysiologically, superficial
electrode motor distal latency, amplitude, nerve
conduction velocity and F response in median, ulnar,
peroneal, tibial nerves and orthodromic sensory distal
latency, amplitude, and nerve conduction velocity in
median, ulnar, sural nerves were studied in both
upper and lower limbs using conventional techniques.
Resting 12-lead electrocardiograms were recorded
with paper speed of 50 mm per second and
standardizations of 0.5 mV per centimeter for
measurement of QTd, corrected QTd (QTcd), JT
dispersion (JTd), and corrected JT dispersion (JTcd).
The QT and JT intervals were measured from
beginning and from the end of the QRS complex,
respectively, to the end of T. If U waves were present,
QT interval was measured to the nadir of the curve
between the T and U waves. None of the patients was
taking any antiarrhythmics or drugs that may alter the
results of QT and JT analysis. In the analyses of the
QT and JT intervals, the values of the maximum QT
and JT interval were used and Bazett’s formula
(QTc=QT / RR) was applied for heart rate correction
(QTc, JTc). The QT and JT dispersion were defined as
the difference between the maximum and the
minimum QT and JT intervals, respectively, in any of
the 12 leads. The study complies with the Declaration
of Helsinki II and the study protocol was approved by

the local ethics committee. Written informed consent
was obtained from each participant. Data are
expressed as mean ± standard deviation and were
computed with SPSS. Wilcoxon Signed Ranks test was
used to compare before and after treatment values.
Results were considered to be statistically and
significantly different when confidence limits
exceeded 95% (P < 0.05).
Results
One patient was excluded from the study because
he did not come for follow-up after treatment. At the
end of the first month, all symptoms associated with
neuropathy improved in all cases. After 10 months
of treatment, median, ulnar, and tibial motor nerve
conduction velocities (P < 0.05) and M-wave
amplitudes (P < 0.01) increased, and distal latencies
and the F-wave latencies (P < 0.05) decreased; ulnar,
sural, and median sensory nerve action potential
amplitudes (P < 0.01), and nerve conduction
velocities (P < 0.05) increased, and distal latencies (P
< 0.05) decreased (Table 2); QTd, QTcd, JTd, and
JTcd (P < 0.05) decreased (Table 3) significantly
compared to the values obtained before treatment.
The greatest changes in sensory nerve action
potential amplitude and QT parameters were
observed in the sensory sural nerve and QTcd,
respectively (Table 1-2). LC was well tolerated over
the study period. Of 30 patients, 2 (6.6%)
experienced excessive sweating and 3 (10%) had the
symptoms of gastrointestinal system but none of the
patients stopped treatment due to side effects.

Table 1. The demographic characteristics of diabetic patients.
Number of total patients
Female gender, N (%)

30
18 (60)

Male age, years

49.92 ± 10.66

Female age, years

53.26 ± 8.08

Duration of diabetes, years

12.8 ± 6.15 (1-30)

Use of insulin

43.3%

Use of oral antidiabetic

56.7%

Number of patients with carpal tunnel syndrome

73.3%
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Table 2. Mean values and comparison between values of some electrophysiological parameters before and after
treatment.

Right median motor

Right ulnar motor

Right peroneal motor

Before treatment

After treatment

distal latency (msec)

4.35 ± 0.8

4.2 ± 0.6*

amplitude (mV)

6.82 ± 2.6

8.27 ± 2.6**

NCV (m/sec)

49.9 ± 9.3

56.3 ± 7.3*

F response latency (msec)

30.5 ± 7.1

28.5 ± 2.4*

distal latency

3.09 ± 0.47

2.72 ± 0.5*

amplitude

8.32 ± 2.15

9.69 ± 1.7**

NCV

52.1 ± 6.1

55.1 ± 11*

F response latency

28.7 ± 2.6

27.3 ± 2*

distal latency

5.0 ± 0.7

4.3 ± 0.4*

amplitude

2.8 ± 1.5

3.2 ± 1.7**

NCV

39.8 ± 4.4

40.2 ± 4.6

F response latency

53.0 ± 6.7

55.3 ± 4.7

distal latency

5.2 ± 0.7

4.7 ± 0.6

amplitude

3.7 ± 1.9

5.8 ± 2.4**

NCV

37.6 ± 4.4

39.6 ± 3.7*

F response latency

55.4 ± 6.1

52.8 ± 5.3*

distal latency

4.9 ± 0.5

4.4 ± 0.8

amplitude

3.0 ± 1.6

3.2 ± 1.4

NCV

40.8 ± 5.8

39.8 ± 3.4

F response latency

48.3 ± 12.6

51.6 ± 8.7

distal latency

5.5 ± 0.9

4.7 ± 0.8*

amplitude

3.9 ± 2.2

6.7 ± 3.3**

NCV

38.7 ± 6.3

42.8 ± 4.2*

F response latency

56.7 ± 4.0

52.9 ± 6.7

Right median sensory a

NCV

32.0 ± 6.1

36.8 ± 4.4*

Right ulnar sensory

NCV

36.3 ± 3.0

38.6 ± 3.5*

Right sural sensory

Amplitude (μV)

4.7 ± 2.8

7.0 ± 7.5**

NCV

29.3 ± 4.3

34.9 ± 6.5*

amplitude (μV)

5.6 ± 3.5

9.1 ± 5.8**

NCV

28.5 ± 5.2

32.0 ± 4.3*

Right tibial motor

Left peroneal motor

Left tibial motor

Left sural sensory

NCV: Nerve conduction velocity; *P < 0.05, **P < 0.01, all in comparison to base line values
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Table 3. Mean values and comparison between values of
ventricular dispersion parameters before and after
treatment (*P < 0.05).
Before treatment

After treatment

QT (ms)

341 ± 35

375 ± 22

JT (ms)

282 ± 35

296 ± 27

QTc (ms)

12 ± 0.63

13 ± 0.84

JTc (ms)

10 ± 0.81

11 ± 0.72

QT-d (ms)

81 ± 33

35 ± 11*

JT-d (ms)

65 ± 22

26 ± 11*

QTc-d (ms)

3 ± 1.3

1 ± 0.35*

JTc-d (ms)

2.7 ± 1.2

0.94 ± 0.33*

RR (ms)

762 ± 141

813 ± 127

Discussion
As yet, there is no effective treatment to prevent
the development or progression of human diabetic
neuropathy. Therapeutic interventions that have been
tried include optimal glycemic control (22), aldosereductase inhibitors (23), gamma linoleic acid (24),
and antioxidants (25). It has been believed that the
plasma carnitine level is an indicator for energy
metabolism of the cell. Carnitine deficiency causes a
defect in energy metabolism and decreases energy
production. Moreover, carnitine deficiency in diabetic
tissues has received considerable attention concerning
its role in the pathogenesis of diabetic neuropathy
(13,14). In a previous study, it has been suggested that
experimental diabetic neuropathy is associated with
depletion of LC in peripheral nerve (26), which may
further limit mitochondrial fatty acid transport and
oxidation (12), and it has also been reported that
treatment with carnitine analogs can improve diabetic
neuropathy and prevent the delay in motor nerve
conduction velocity and electrophysiological
abnormalities (13,14,26-28). We found that LC
improved diabetic neuropathy and prevented the
delay in motor nerve conduction velocity and other
electrophysiological abnormalities similar to the
results of the previous studies (13,14,26-28).
In addition, LC improves nerve regeneration after
crush injury (29), neuromuscular dysfunction in
normal rats (30), various abnormalities in cardiac

function and biochemistry after ischemia or
reperfusion (31), HIV-associated antiretroviral toxic
neuropathy (32), and chemotherapy-induced
neuropathy after cisplatin or paclitaxel treatment
without showing any interference with the antitumor
activity of the drugs (33). However, the effect of LC
on the increased QTd has never been studied before. A
prolonged QT interval, as measured with a standard
electrocardiogram (ECG), is associated with an
increased risk of arrhythmias and sudden death (18).
Diabetic patients have increased QTd compared to
non-diabetics even those without arterial
hypertension and cardiovascular complications and
with recent diagnosis (34). Furthermore, a prolonged
QTd has been shown to be a strong and independent
predictor of cardiac mortality in diabetes mellitus
(DM) (35), and it has been reported that QT interval
parameters give additional prognostic information in
patients with DM, beyond that obtained from
traditional risk factors (19). Recently, it has been
shown that l-carnitine is able to increase hair shaft
elongation and prolong anagen by upregulation of
proliferation and downregulation of apoptosis in
organ-cultured human scalp hair follicles (36). In this
study, we found that the efficacy of LC in the
treatment of increased QTd in patients with DM was
significant when compared to the baseline values.
Hyperglycemia-driven mitochondrial overproduction of ROS has recently been identified as the
underlying biochemical abnormality in diabetic
complications (37). LC would decrease the Ca++
concentration by improving Na+/K+-ATPase activity,
as previously reported (38). The efficacy of LC in the
treatment of increased QTd in patients with DM may
be due to the restored myocardial ischemia.
Hyperglycemia-induced ROS production in
mitochondria not only occurs in endothelial cells but
also in platelets. The result of increased ROS
production of platelets is, among others, increased
aggregation and an increased release of cytokines (39).
Carnitine protects the cell membrane and DNA
against the damage induced by free oxygen radicals. It
prevents protein oxidation and pyruvate and lactate
oxidative damage (40,41). Our results are in
accordance with the results of the previous studies.
In conclusion, LC may improve peripheral
neuropathy and ventricular dispersion and is well
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tolerated in patients with diabetes, which may be
useful in preventing the increased incidence of
arrhythmias and sudden death observed in such
patients. The beneficial effects of LC on the

progression of neuropathy and risk for cardiovascular
event must be studied in large, randomized, and
controlled trials before changes in clinical practice can
be advocated.
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